anti-Mouse Cytokeratin, Acidic (Type I or LMW), DyLight 488, Clone: SPM115, Novus Biologicals
Mouse Monoclonal Antibody
Manufacturer: Novus Biologicals NBP234393G
DescriptionCytokeratin, Acidic (Type I or LMW) Monoclonal antibody specifically detects Cytokeratin, Acidic (Type I or LMW) in Human, Mouse, Rat, Bovine, Canine, Chicken, Primate, Rabbit, Reptile samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.
|Cytokeratin, Acidic (Type I or LMW)|
|Western Blot, Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen|
|Human epidermal keratin|
|Store at 4C in the dark.|
|Human, Mouse, Rat, Bovine, Canine, Chicken, Primate, Rabbit, Reptile|
|Western Blot, Flow Cytometry, ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin)|
|50mM Sodium Borate with 0.05% Sodium Azide|
|Protein G purified|
|This MAb recognizes the 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19) keratins of the acidic (Type I or LMW) subfamily. Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. The acidic keratins have molecular weights (MW) of 56.5, 55, 51, 50, 50, 48, 46, 45, and 40kDa. MAb SPM116 recognizes the 65-67, 64, 59, 58, 56, and 52kDa keratins of basic subfamily. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. SPM115/SPM116 is a broad spectrum anti pan-keratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok
For Research Use Only